For research use only. Not for therapeutic Use.
Vanucizumab（Cat No.:I042248）is a monoclonal antibody designed to inhibit both VEGF-A and Angiopoietin-2, two key proteins involved in angiogenesis (the formation of new blood vessels). By targeting these molecules, Vanucizumab aims to block abnormal blood vessel growth that is commonly seen in various cancers and retinal diseases. It has been studied for its potential to treat conditions like wet age-related macular degeneration (AMD) and various solid tumors. Clinical trials are exploring its efficacy and safety, with the goal of providing a more effective therapy for diseases driven by excessive angiogenesis.
| Catalog Number | I042248 |
| CAS Number | 1448221-05-3 |
| Purity | ≥95% |
